Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 11/20 | 0.70 |
| ▸ | RIPK2 | O43353 | 8/20 | 0.69 |
| ▸ | EGFR | P00533 | 10/20 | 0.68 |
| ▸ | ABL1 | P00519 | 9/20 | 0.68 |
| ▸ | ABL2 | P42684 | 9/20 | 0.68 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | LYN | P07948 | 2/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.60 |
| ▸ | INSR | P06213 | 1/20 | 0.60 |
| ▸ | NPM1 | P06748 | 1/20 | 0.60 |
| ▸ | CSF1R | P07333 | 1/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | IGF1R | P08069 | 1/20 | 0.60 |
| ▸ | MET | P08581 | 1/20 | 0.60 |
| ▸ | ROS1 | P08922 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | KIT | P10721 | 1/20 | 0.60 |
| ▸ | BCR | P11274 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2071933 | 0.95 | SRC (0.76) | SRCRIPK2EGFRABL1ABL2 | |
| SCHEMBL23966913 | 0.87 | SRC (0.73) | SRCRIPK2EGFRABL1ABL2 | |
| SCHEMBL20351628 | 0.85 | SRC (0.80) | SRCRIPK2EGFRABL1ABL2 | |
| SCHEMBL2072372 | 0.83 | SRC (0.60) | SRCRIPK2EGFRABL1ABL2 | |
| SCHEMBL23966669 | 0.83 | SRC (0.61) | SRCRIPK2EGFRABL1ABL2 | |
| SCHEMBL30180688 | 0.83 | SRC (0.61) | SRCRIPK2EGFRABL1ABL2 | |
| SCHEMBL28928811 | 0.82 | EGFR (0.71) | SRCRIPK2EGFRABL1ABL2 | |
| SCHEMBL28928810 | 0.82 | EGFR (0.71) | SRCRIPK2EGFRABL1ABL2 | |
| SCHEMBL18044541 | 0.81 | SRC (0.81) | SRCRIPK2EGFRABL1ABL2 | |
| SCHEMBL23966767 | 0.79 | RIPK2 (0.69) | SRCRIPK2EGFRABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| CN-115843272-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-03-24 | — | — | CN | disclosed |
| EP-4146348-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-2021242505-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-11161852-B1 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | SRC 639/4885RIPK2 56/4885EGFR 4553/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | SRC 639/4885RIPK2 56/4885EGFR 4553/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | SRC 3388/4885RIPK2 23/4885EGFR 4872/4885 |
| US-11161852-B1 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | SRC 639/4885RIPK2 56/4885EGFR 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.